Clinical Trials
65 trialsPembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
National Cancer Institute (NCI)
SUP-R
Institut Claudius Regaud
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Roswell Park Cancer Institute
ADONIS
Pfizer
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
M.D. Anderson Cancer Center
STROKER
Sun Yat-sen University
A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma
Imbioray (Hangzhou) Biomedicine Co., Ltd.
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Xynomic Pharmaceuticals, Inc.
COMPARZ
Novartis
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Novartis
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Mayo Clinic
IVY
Eli Lilly and Company
OPTI-DOSE
University Medical Center Groningen
IO-PAZ
Novartis
Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma
RenJi Hospital
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
City of Hope Medical Center
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
Academic and Community Cancer Research United
Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5
Cancer Trials Ireland
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Bristol-Myers Squibb
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
NIVOSWITCH
AIO-Studien-gGmbH
PROTECT
Novartis
PRINCIPAL
Novartis
PIPELINE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)
Abramson Cancer Center at Penn Medicine
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
Dana-Farber Cancer Institute
Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)
Novartis
HYPAZ
Cambridge University Hospitals NHS Foundation Trust
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
Virginia Commonwealth University
FARETES
Kidney Cancer Research Bureau
SOGANG
Spanish Oncology Genito-Urinary Group
Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma
University of Michigan Rogel Cancer Center
Study To Assess Long Term Safety Of Pazopanib
Novartis
BERAT
Central European Society for Anticancer Drug Research
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
Case Comprehensive Cancer Center
SPAZO
Spanish Oncology Genito-Urinary Group
Neoadjuvant Pazopanib in Renal Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
GlaxoSmithKline
A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients
GlaxoSmithKline
Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034
GlaxoSmithKline
VEG111485: A QTc Study of Pazopanib
GlaxoSmithKline
A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes
GlaxoSmithKline
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
GlaxoSmithKline
An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma
GlaxoSmithKline
FLIPPER
iOMEDICO AG
OPERA
Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.